Vaccine Development

Nonprimed dendritic cells enhance immune response

Published in Vaccine Weekly, June 19th, 2002

by Maria G. Essig, MS, ELS, senior medical writer - The addition of nonprimed dendritic cells to the same site targeted by the MUC1 DNA vaccine enhanced immunity against lymphoma cells in a murine model, researchers in Japan report.

K. Kontani and colleagues at Shiga University of Medical Science in Japan immunized C57BL/6 mice with a DNA vaccine that encoded for MUC1 polypeptide. Upon challenge with EL4-muc, MUC1-transfected syngeneic lymphoma cells, the immunized mice rejected the tumors. However, the DNA vaccine was unable to prevent progression of tumor growth in EL4-muc tumor-bearing mice.

"This animal model is useful for developing DNA...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2002-06-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry